Robert Menendez actually said...
The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.
Context
Menendez criticizes the lack of oversight in the PBM market.
03/29/2023